New Presentation

Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information

Investor Relations

Stock Information






52 week Low/High

Day Low/High

Company Overview

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines. MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center (MSK). The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.

Contact Information

Investor Relations

Jenny Stephens
T: 858-259-9405 x302

Transfer Agent

Computershare Investor Services PLC

Latest Financial Results

Q1 2017

Quarter Ended Mar 31, 2017
Report Figure

Latest 10-K

For Fiscal Year 2016

Download 10-K

Sign Up for Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign Up Now